Navigation Links
Moleac Announces the Beneficial Effect of NeuroAiD (TM) (MLC 901) in Protecting the Brain Against Global Ischemia
Date:6/27/2011

SINGAPORE, June 27, 2011 /PRNewswire-Asia/ -- In June 2011, "Neuropharmacology" published a paper establishing NeuroAiD's reparative effects on global cerebral ischemia. Global cerebral ischemia is subsequent to cardiac arrest, reversible severe hypotension or other situations depriving the brain of oxygen and glucose. It results in residual neurologic deficits, ranging from mild cognitive impairment to severe neurological deficits, for which there is no treatment to date.

The research paper shows that NeuroAiD post global ischemia protects the neurons against ischemic injury in the CA1 region of the hippocampus which plays a critical role in the consolidation of information from short-term to long-term memory. In animal models, NeuroAiD inhibits neuronal cell death and protects neurons against DNA fragmentation by activating phosphorylation of the AKT protein and reducing oxidative stress. This corresponds to the better recovery of cognitive and motor deficits observed post stroke in clinical experiences.  

This study builds on previous research conducted in 2010 at the Institute of Molecular Pharmacology of the CNRS (French National Centre for Scientific Research) establishing NeuroAiD's neuroprotective and neuroreparative properties, and explaining the neurological recovery seen in post stroke patients.  The results established that NeuroAiD triggers the synthesis of the Brain Derived Neurotrophic Factor (BDNF), which is known to promote neuroplasticity. Indeed, NeuroAiD induces neurogenesis in rodent and human cells, and stimulates the development of new neuronal circuits of information by promoting cell proliferation and the development of dense axonal and dendritic networks. The recent data further confirms the neuroprotective effect of NeuroAiD and encourages prescribing it as soon as possible after a stroke so as to ensure a higher level of protection.

The lead researchers behind this new paper are Catherine Heurteaux and Michel Lazdunski, world-renowned specialists in pharmacology and neuroscience, who supervised a team of experts in cerebrovascular pathologies and therapeutics from the Institute of Molecular and Cellular Pharmacology at the CNRS in France.

Previous trials and clinical reports conducted in Asia have already evidenced NeuroAiD's safety and efficacy in post stroke rehabilitation, even when taken several months after the stroke's onset. This paper comes after the publication of three clinical peer reviewed papers in the first half of 2011. Firstly, the European Journal of Internal Medicine published a paper establishing a significant increase of Cerebral Blood Flow velocity after 3 months in stroke patients treated with NeuroAiD as compared to placebo. These results, in matching a better functional outcome, suggested increased angiogenesis and microcirculation activity. Secondly, Neuronal Regeneration Research published a paper suggesting that NeuroAiD may increase the recovery of vision deficits in post stroke Homonymous Hemianopsia patients. The patients in the NeuroAiD group demonstrated a 50% increase in therapeutic effects as compared to the Piracetam group. Lastly, Stroke Research and Treatment published a double-blind placebo-controlled clinical trial which was conducted on 150 patients having suffered from stroke less than 3 months ago. NeuroAiD showed a better motor recovery than placebo, and was safe as an add-on to standard ischemic stroke medications, especially in severe and moderate cases.

"This is good news for the patients", commented David Picard, CEO of Moleac. "The number of publications on NeuroAiD since the beginning of the year shows increased interest and reach for NeuroAiD. The latest papers further confirm how NeuroAiD benefits post stroke patients in cognitive and motor recovery. There is a strong urge for us to expand our clinical work to address the needs of post-cardiac arrest patients. In Europe alone, 350,000 people suffer cardiac arrest and many of them are left to cope with cognitive disabilities. For Picard to conclude: "By leveraging our considerable pharmacological research strengths along with extensive clinical studies, we are happy to make new breakthroughs in a broad range of neurologic disorders. We will dedicate our efforts in further investigating the potential of NeuroAiD in treating neurological deficits induced by global ischemia, which could present an interesting strategy for the patients who undergo cardiac arrest."

About Moleac
http://www.moleac.net
Moleac is a Singapore-based biopharmaceutical company dedicated to finding and developing new medicines for the unmet needs of patients worldwide.

About NeuroAiD™
http://www.NeuroAiD™.com
NeuroAiD™ is a stroke treatment to help stroke patients achieve a faster and better recovery. NeuroAiD is derived from natural components, carefully selected for their efficacy and absence of side effects. It currently reaches out to patients in over 25 countries.

Contact details:
Kasia Kaminska
Tel: +65-8533-0652
Email: kasia.kaminska@moleac.net


'/>"/>
SOURCE Moleac
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. NIAID announces 25 new awards to develop radiation countermeasures
2. Aware Announces Q3 2008 Earnings Conference Call
3. Governor Doyle announces historic genomic research collaboration
4. BIO-key(R) Announces Additional $245,000 in Third Quarter Public Safety Orders
5. NARSAD announces 2008 Prizes for Outstanding Achievement in Research on Mental Health Disorders
6. Parkinsons Disease Foundation announces award of $150,000
7. Jefferson Department of Surgery announces new pancreas tumor registry
8. NAS announces initiative to connect entertainment industry with top experts
9. Elsevier announces winners of 3rd Annual Scopus Young Indian Scientist Award
10. VUANCE Announces Crime Scene Security and Evidentiary Tracking Development Project
11. WCC Announces Version 6 of its ELISE Smart Search and Match Platform for Employment and Biometric Matching
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2016)... , PROVO and ... -- Newborn Screening Ontario (NSO), which operates the highest ... for molecular testing, and Tute Genomics and UNIConnect, leaders ... technology respectively, today announced the launch of a project ... sequencing (NGS) testing panel. NSO has ...
(Date:3/18/2016)... , March 18, 2016 ... Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure ... & security companies in the border security market and the ... and Europe has led visiongain ... companies improved success. --> defence & security ...
(Date:3/15/2016)... --> --> ... Research "Digital Door Lock Systems Market - Global Industry Analysis, ... global digital door lock systems market in terms of revenue ... forecast to grow at a CAGR of 31.8% during the ... enterprises (MSMEs) across the world and high industrial activity driving ...
Breaking Biology News(10 mins):
(Date:5/27/2016)... ... May 27, 2016 , ... NeuMedics Inc. is pleased to announce that ... Innovation Northwest on June 2, 2016. The session begins at 1:10 PM and Iain ... can be successfully used as a topical agent and a treatment for ophthalmic complications ...
(Date:5/27/2016)... NEW YORK , May 27, 2016 ... state, but investors playing in this space know that volatility ... this morning,s featured companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: ... CTIC ), Lpath Inc. (NASDAQ: LPTN ), and ... now and gain access to the technical alerts for these ...
(Date:5/26/2016)... ... ... After several promising treatments in Panama using stem cell ... in Panama, a 6 year-old Duchenne’s muscular dystrophy patient received his first umbilical ... approval of a second application for a single patient, investigational new drug (IND) ...
(Date:5/25/2016)... ... May 25, 2016 , ... The Ankle Plating ... options designed to address fractures of the distal tibia and fibula. This system ... Ankle Plating System 3 is composed of seven plate families that span the ...
Breaking Biology Technology: